Mandate

Vinge has advised Marginalen Bank regarding a substitution of issuer for its existing capital notes and the issuance of new capital notes

June 03, 2025 Banking and Finance

Vinge has advised Marginalen Bank Bankaktiebolag (publ) regarding a change of issuer for its outstanding capital notes, consisting of SEK 560 million in Tier 2 Capital Notes and SEK 200 million Additional Tier 1 Capital Notes. ESCO Marginalen AB (publ) will assume all obligations under the existing capital notes in connection with the transaction, while Marginalen Bank issues new capital notes in a corresponding amount by way of set-off.

Vinge assisted with the application for approval of the issuer substitution with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen), as well as with obtaining the consent of the noteholders through written procedures and coordination with Nasdaq regarding the continued admission to trading of the existing capital notes on Nasdaq Stockholm.

ABG Sundal Collier acted as the financial advisor for the transaction.

Vinge’s team consisted of Mikael Ståhl, Arvid Weimers, Henrik Schön, Katja Häglund and Julia Gudmundsson.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026